- The company unveiled a series of new studies highlighting the
prognostic value of its imaging biomarkers in patients
with fibrotic lung disease
- The studies reflect the company's expanding Life Science
partnerships and academic collaborations with luminary research
centers in the lung space
OXFORD, England and
CHICAGO, May 22, 2024 /PRNewswire/ -- Brainomix, a pioneer
in artificial intelligence (AI) imaging solutions to enable
precision medicine, announced a series of new studies that were
presented this week at the American Thoracic Society (ATS)
Conference in San Diego.
"The studies presented this week at ATS are a reflection of our
continual focus on scientific excellence and academic collaboration
with both world-class institutions as well as with Life Science
partners," noted Dr Michalis
Papadakis, CEO and Co-Founder of Brainomix. "The results
highlight the prognostic value of our novel Brainomix lung imaging
biomarkers to accurately predict disease progression in Idiopathic
Pulmonary Fibrosis (IPF) and non-IPF patients."
Key abstracts accepted and presented at ATS included:
- "Diagnosis and the role of imaging biomarkers in predicting
outcomes for patients with Non-IPF Fibrotic ILD," was a
research collaboration with Heidelberg University in which a cohort
of 347 patients with non-IPF over a 10-year period was analyzed
with Brainomix's novel lung imaging biomarker, the weighted
reticulovascular score (WRVS). The results indicated WRVS was a
strong predictor for death and independent risk factor for 10%
Forced Vital Capacity (FVC) decline. "This study has demonstrated
the prognostic value of the Brainomix WRVS imaging biomarker, which
can be a valuable predictor of progressive disease in this cohort
of patients with fibrotic non-IPF ILD," noted Prof Dr
Michael Kreuter, Director for
the Lung Center Mainz.
- "Differences in lung biomarker scores between treatment groups
in post-hoc analysis of the ATLAS inhaled pirfenidone solution
(AP01) for IPF clinical trials" was a research collaboration with
Avalyn Pharma, a Seattle-based
clinical-stage biopharmaceutical company. Brainomix lung imaging
biomarkers (including WRVS) were studied in a post-hoc analysis of
Avalyn's phase 1b clinical trial of
inhaled pirfenidone (ATLAS study) in patients with IPF, with
results showing that WRVS was associated with risk of future IPF
progression in the low-dose pirfenidone group. "This research can
assist in the optimisation of AI imaging tools to enrich clinical
trials for progressive patients, to facilitate matching treatment
arms and further explore novel trial end points," Dr
Peter George, Senior Medical
Director at Brainomix and Clinical Lead for ILD at Royal Brompton
Hospital in London.
- "Lung CT biomarkers can stratify patients at risk of Idiopathic
Pulmonary Fibrosis progression at 52 weeks: post-hoc analysis from
a randomised control trial" was a research collaboration with
AstraZeneca using the Phase 2 IPF tralokinumab clinical trial. WRVS
was shown to accurately predict patients at baseline at risk of
52-week FVC decline. "These data suggests that our WRVS biomarker
may enable more sophisticated design of future clinical trials,"
said Ross Stewart, Senior
Business Development Manager, Pharma Partnerships, at
Brainomix.
About Brainomix
Brainomix specializes in the creation of AI-powered software
solutions to enable precision medicine for better treatment
decisions in stroke and lung fibrosis. With origins as a spin-out
from the University of Oxford, Brainomix is an expanding
commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries.
A private company, backed by leading healthtech investors,
Brainomix has innovated award-winning imaging biomarkers and
software solutions that have been clinically adopted in hundreds of
hospitals worldwide. Its first product, the Brainomix 360 stroke
platform, provides clinicians with the most comprehensive stroke
imaging solution, driving increased treatment rates and improving
functional independence for patients.
To learn more about Brainomix and its technology
visit www.brainomix.com, and follow us
on Twitter, LinkedIn and Facebook.
Contacts
Jeff Wyrtzen, Chief Marketing
& Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730
Media enquiries
Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585
Logo -
https://mma.prnewswire.com/media/1989193/Brainomix_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/brainomix-showcases-growing-evidence-for-its-novel-ai-based-imaging-biomarkers-in-lung-fibrosis-302152575.html